GALECTIN THERAPEUTICS INC
GALECTIN THERAPEUTICS INC (GALT): 1 pipeline candidate · ~11 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
11.3 months
D/E -1.11 · 0% dilution
Lead: Phase 2/Phase 3
1 candidate
N/A
4 buys · 11 sells (180d)
A transparent, data-derived signal for GALECTIN THERAPEUTICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$166.9M
Cash
$14.1M
Quarterly Burn
$3.9M
Runway
11.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| belapectin | Phase 2/Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
99
Total value held
$45.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,933,084 | $11.0M |
| marshall wace, llp | 1,219,912 | $3.4M |
| osaic holdings, inc. | 1,122,670 | $3.1M |
| susquehanna international group, llp | 1,073,202 | $3.0M |
| great point partners llc | 800,000 | $2.2M |
| blackrock, inc. | 799,237 | $2.2M |
| millennium management llc | 798,434 | $2.2M |
| geode capital management, llc | 612,786 | $1.7M |
| two sigma investments, lp | 467,063 | $1.3M |
| commonwealth equity services, llc | 367,113 | $1.0M |
Showing top 10 of 99 institutional holders of GALECTIN THERAPEUTICS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in GALECTIN THERAPEUTICS INC's pipeline?
GALECTIN THERAPEUTICS INC (GALT) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is GALECTIN THERAPEUTICS INC's lead drug candidate?
GALECTIN THERAPEUTICS INC's most advanced tracked candidate is belapectin (Phase 2/Phase 3) for Prevention of Esophageal Varices.
What is GALECTIN THERAPEUTICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GALECTIN THERAPEUTICS INC has approximately 11.3 months of cash runway.
What is GALECTIN THERAPEUTICS INC's market capitalization?
GALECTIN THERAPEUTICS INC's market capitalization is approximately $166.9M.
Who is the CEO of GALECTIN THERAPEUTICS INC?
Mr. Joel Lewis CPA is the chief executive officer of GALECTIN THERAPEUTICS INC (GALT).
Get the full picture on GALECTIN THERAPEUTICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.